News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Encap Drug Delivery Agrees Colonic Drug Delivery Licensing Deal with University of London


9/3/2009 2:52:53 PM

Livingston, United Kingdom, 3rd September 2009 / b3c newswire / - Encap Drug Delivery, the leading provider of development and manufacturing services to the pharmaceutical industry, today announced that it has entered into a licensing agreement with The School of Pharmacy, University of London for the use of their drug delivery system, PHLORALTM. This unique coating technology is designed to target the release of drugs to the colon and will form part of a range of colonic delivery systems promoted by Encap under the name ENCODETM (Encap Colonic Delivery) Recently colonic drug delivery has gained increased importance, not just for treatment of local diseases associated with the colon, e.g. Crohn's disease, ulcerative colitis, colorectal cancer and IBS, but also for its potential as a site for the absorption of certain molecules due to the decreased levels of efflux transporters and membrane-bound metabolic enzymes known as cytochromes. Its potential suitability for the oral delivery of peptides and proteins, oligonucleotides and vaccines is also an area of increasing interest.

Existing colonic systems generally involve coating the dosage unit with polymeric materials that will not normally dissolve in the low pH of the stomach or upper intestine but will dissolve in the higher pH of the lower intestine. Coatings that rely on a pH dependant system have the potential to be unreliable due to the large intra and inter patient variability in transit times and luminal pH. The new PHLORALTM technology represents a significant improvement in colonic delivery providing ‘fail-safe’ delivery of drug to the target site by employing two complimentary mechanisms to trigger drug release. As well as a pH dependant coating it also incorporates a component which is broken down specifically by the microbiota in the colonic region.

The power of the new technology has been demonstrated in a recently published scintigraphic study in healthy volunteers (Ibekwe, Khela, Evans and Basit, Alimentary Phamacology & Therapeutics 28(7):911-6, 2008). Dosage units with the combination coating all disintegrated in the colonic area as desired whereas many units coated exclusively with a commercially available pH coating passed through the gastrointestinal tract intact and failed to disintegrate. One of the drawbacks to colonic delivery is the relatively low amount of water that is available for dissolution of dosage forms in this part of the gastrointestinal tract. The combination of a reliable colonic targeting technology and the delivery of drugs in a liquid dosage form using Encap’s liquid fill technologies may provide a significant advance for the delivery of a wide range of drugs to the colon.

Encap’s Chief Operating Officer, Dr Stephen Brown said “This deal with The School of Pharmacy is an ideal strategic fit for Encap Drug Delivery as we already have a portfolio of drug delivery technologies available for oral dose forms. The ability to use the PHLORALTM technology combined with the flexibility afforded by our liquid fill hard capsule technology, allows us to now offer clients a system with the confidence that colonic delivery will be achieved.”

Link to the news release

About Encap Drug Delivery - www.encapdrugdelivery.com

Encap was established in 1989 and is a global provider of oral drug delivery and pharmaceutical development services. The company provides clients with fully integrated analytical and formulation development services, clinical trial manufacturing and high volume commercial manufacturing. Encap’s state-of-the-art facility in the UK is the world’s largest development and manufacturing facility dedicated to liquid filled hard capsules.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES